Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma by unknown
Mazan-Mamczarz et al. Cell Communication and Signaling  (2015) 13:15 
DOI 10.1186/s12964-015-0091-0RESEARCH Open AccessDistinct inhibitory effects on mTOR signaling by
ethanol and INK128 in diffuse large B-cell
lymphoma
Krystyna Mazan-Mamczarz1†, Raymond J Peroutka1†, James J Steinhardt1, Moriah Gidoni2, Yongqing Zhang3,
Elin Lehrmann3, Ari L Landon1, Bojie Dai1, Simone Houng1, Parameswary A Muniandy1, Sol Efroni2,
Kevin G Becker3 and Ronald B Gartenhaus1,4*Abstract
Background: The mechanistic target of rapamycin, (mTOR) kinase plays a pivotal role in controlling critical cellular
growth and survival pathways, and its aberrant induction is implicated in cancer pathogenesis. Therefore,
suppression of active mTOR signaling has been of great interest to researchers; several mTOR inhibitors have been
discovered to date. Ethanol (EtOH), similar to pharmacologic mTOR inhibitors, has been shown to suppress the
mTOR signaling pathway, though in a non-catalytic manner. Despite population studies showing that the consumption
of EtOH has a protective effect against hematological malignancies, the mechanisms behind EtOH’s modulation of
mTOR activity in cells and its downstream consequences are largely unknown. Here we evaluated the effects of EtOH
on the mTOR pathway, in comparison to the active-site mTOR inhibitor INK128, and compared translatome analysis of
their downstream effects in diffuse large B-cell lymphoma (DLBCL).
Results: Treatment of DLBCL cells with EtOH suppressed mTORC1 complex formation while increasing AKT
phosphorylation and mTORC2 complex assembly. INK128 completely abrogated AKT phosphorylation without
affecting the structure of mTORC1/2 complexes. Accordingly, EtOH less profoundly suppressed cap-dependent
translation and global protein synthesis, compared to a remarkable inhibitory effect of INK128 treatment. Importantly,
EtOH treatment induced the formation of stress granules, while INK128 suppressed their formation. Microarray analysis
of polysomal RNA revealed that although both agents primarily affected cell growth and survival, EtOH and INK128
regulated the synthesis of mostly distinct genes involved in these processes. Though both EtOH and INK128 inhibited
cell cycle, proliferation and autophagy, EtOH, in contrast to INK128, did not induce cell apoptosis.
Conclusion: Given that EtOH, similar to pharmacologic mTOR inhibitors, inhibits mTOR signaling, we systematically
explored the effect of EtOH and INK128 on mTOR signal transduction, components of the mTORC1/2 interaction and
their downstream effectors in DLBCL malignancy. We found that EtOH partially inhibits mTOR signaling and protein
translation, compared to INK128’s complete mTOR inhibition. Translatome analysis of mTOR downstream target genes
established that differential inhibition of mTOR by EtOH and INK128 distinctly modulates translation of specific subsets
of mRNAs involved in cell growth and survival, leading to differential cellular response and survival.
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The mechanistic target of rapamycin, or mTOR, is a
serine/threonine kinase that has been demonstrated to
govern a multitude of cellular processes such as survival,
growth, metabolism, cell cycle progression, cytoskeletal
organization, protein synthesis and autophagy. Function-
ally, mTOR coordinates the cell’s response to upstream
signaling events such as nutrient levels, growth factors,
amino acids, oxygen and stress. One or both of the multi-
protein mTOR complexes, mTORC1 and mTORC2, con-
vey these signaling events in their activated states. The
mTORC1 protein complex contains the unique com-
ponents of the regulatory associated protein of mTOR
(raptor), the proline-rich AKT substrate 40 kDa (PRAS40)
and the 12 kDa FK509-binding protein (FKBP12), while
mTORC2 exclusively contains the rapamycin-insensitive
companion of mTOR (rictor) and the mammalian stress-
activated MAP kinase-interacting protein 1 (mSin1) (re-
viewed by Laplante and Sabatini) [1]. Protein synthesis is
the downstream signaling process most frequently studied
under the control mTORC1. mTORC1 promotes protein
synthesis through the phosphorylation of eukaryotic
translation initiation factor 4E (eIF4E) binding protein
1 (4E-BP1) and S6 kinase 1 (S6K1 or p70S6K) (reviewed
by Ma and Blenis) [2]. Phosphorylation of 4E-BP1 results
in its release of binding to, and inhibition of, eIF4E. eIF4E
is then free to form the eIF4F complex and participate in
cap-dependent translation. Phosphorylation of p70S6K in
turn results in the activation of ribosomal protein S6
(RPS6) and other translational regulators that further en-
hance translation initiation and elongation. Additionally,
active mTORC1 promotes the expression of rRNA and
tRNA via interaction with RNA polymerase I (Pol I) and
de-repression of Maf1, respectively [3,4]. The summation
of active mTORC1 complex’s activities ultimately results
in the upregulation of overall protein synthesis while en-
hancing cell survival mechanisms.
With respect to mTORC1, there has been considerably
much less research devoted to the study of the mTORC2
protein complex. It was initially thought that mTORC2
was insensitive to rapamycin, however studies have
since demonstrated that long-term treatment can affect
mTORC2 signaling in some cell types. Active mTORC2
modulates pathways such as metabolism, survival, apop-
tosis and growth through the phosphorylation of effector
kinases such as the RAC-alpha serine/threonine-protein
kinase (AKT) [1]. While the mTORC2 complex partially
activates AKT by phosphorylating Ser473, this event fa-
cilitates the action of PDK1, which can further enhance
the activity of AKT by phosphorylating the Thr308 resi-
due [5]. The activity of the serum/glucocorticoid-regu-
lated kinase 1 (SGK-1) has been demonstrated to rely
solely on the activity of the mTORC1 complex. SGK-1
controls FoxO1 and the tumor suppressor FoxO3,modulating both cellular metabolism and survival, re-
spectively [1].
Given the potential power of mTOR signaling with
regard to cellular processes, the pathway has been an at-
tractive therapeutic target for various maladies including
cancer, type II diabetes, obesity and neurodegeneration.
Dysregulation of mTOR signaling in cancer has been
observed to result from both aberrant upstream and
downstream signaling pathways. Recent studies indicate
that mTOR-mediated dysregulation of translation may
play a critical role in the development, maintenance and
progression of certain malignancies [1]. To date, several
rapamycin analogs (rapalogs) have been developed and
tested in the clinic, however they have shown limited
efficacy. The presence of negative feedback loops, ori-
ginating from mTOR1 signal transduction, has been
proposed as limiting with respect to the rapalogs [1].
Another proposed limitation of rapalog treatment is the
partial inhibition of 4E-BP1 [6], which still allows for
translation and pro-proliferative/anti-apoptotic signaling
in tumors. More recently, two mTOR kinase domain in-
hibitors (TORKinibs; AZD8055 and INK128) targeting
both members of the mTOR complex (mTORC1 and
mTORC2), have been developed and are currently being
evaluated in several clinical trials [6,7]. Initial results
have shown catalytic inhibitors having single-agent activity
apparently higher than that seen with rapalogs. Clinical re-
sponses to TORKinibs have thus far been seen in patients
with non-small cell lung cancer, hepatocellular carcinoma,
and estrogen receptor positive breast cancer, with poten-
tial utility in diffuse large B-cell lymphoma [8-11].
Together with the rapalogs and recently developed
catalytic inhibitors, EtOH has been reported to modulate
mTOR signaling and protein synthesis [12-16], yet the
mechanisms behind its impact on mTOR component
activity (mTORC1 and mTORC2) and its downstream
consequences are still under investigation. Interestingly,
multiple population studies have shown a decreased inci-
dence of hematological malignancies including leukemia,
myeloma, non-Hodgkin lymphoma, and Hodgkin disease
[17-21]. Notwithstanding several studies performed on
muscle tissue [12,13] or brain cells [22-25], there are very
limited studies of EtOH impact on human neoplastic
cells [14].
Given that both EtOH and TORKinibs inhibit mTOR
signaling, we attempted to systematically compare the
effect of EtOH and INK128 on mTOR signal transduction
and interaction between components of the mTORC1/2
complexes in diffuse large B-cell lymphoma (DLBCL)
malignancy. We used SUDHL-2 cells, representing an ag-
gressive activated B-cell-like (ABC) DLBCL, and SUDHL-
4 cells representing germinal center B cell-like (GCB)
DLBCL type which usually has a better clinical prognosis.
We also evaluated the differences in the mechanisms
Mazan-Mamczarz et al. Cell Communication and Signaling  (2015) 13:15 Page 3 of 17underlying EtOH and INK128 activity and performed
head to head genome-wide characterization of their
downstream translationally controlled genes. We found
that, in contrast to INK128, which induced complete
inhibition of mTORC1 and mTORC2 activity, EtOH
decreased mTORC1 activity and complex formation,
while concurrently activating AKT phosphorylation and
mTORC2 assembly. Consequently, EtOH-triggered sup-
pression of cap-dependent translation and global protein
synthesis was less profound as compared to the inhibitory
effect of INK128. Importantly, EtOH elicited incomplete
inhibition of mTOR signaling and translation while in-
ducing stress granule (SG) assembly, whereas INK128
induced full mTOR inactivation and impaired SG for-
mation. Furthermore, microarray analysis of polysomal
RNA revealed that EtOH and INK128, through differential
inhibition of the mTOR pathway, distinctly modulated the
DLBCL translatome. While both agents primarily affect a
group of functionally related mRNAs, which are involved
in cell growth and survival, EtOH and INK128 diffe-
rentially affect the synthesis of distinct subsets of proteins
involved in these processes. Finally, both EtOH and
INK128 inhibited cell cycle and proliferation, and induced
autophagy; EtOH, however, did not induce cell apoptosis.
In summary, we provide evidence that EtOH partially in-
hibits mTOR activity as compared to full inhibition of
mTORC1/mTORC2 by INK128 in DLBCL, which results
in the differential regulation of downstream mTOR targets
and consequent cellular responses.
Results
EtOH and INK128 differentially affect mTORC1/2 function
in DLBCL cell lines
The disruption of mTOR complexes by different pharma-
cological and genetic approaches results in varied effects
with regard to AKT phosphorylation, protein translation,
cell growth and proliferation. EtOH was reported to in-
hibit mTORC1 signaling and decrease protein synthesis
[14,15,22,24]. INK128 (MLN0128) was identified as a
highly specific ATP competitive inhibitor of mTOR [26].
Although EtOH and INK128 are very different com-
pounds, they both affect mTOR signaling pathway com-
ponents; we therefore set out to evaluate the mechanisms
underlying their activity by comparing both mTOR in-
hibitors in parallel. For EtOH treatment, we used a
range of concentrations (20, 40, 100 mM), which were
in agreement with previous research [12-14,23,25]. Fol-
lowing INK128 dose response studies (Additional file 1:
Figure S1), 40 and 200 nM concentrations were deter-
mined to be optimal for obtaining equipotent inhibitory
effects on mTOR signaling with regard to EtOH treat-
ment. Since there is no evidence for catalytic inhibition of
mTOR by EtOH, the prototypical allosteric inhibitor,
rapamycin, was used for extensive comparisons.Exposure to either EtOH or INK128 inhibited the
mTORC1 signaling pathway, as indicated by a dose-
dependent reduction in the phosphorylation of mTOR
on Ser2448 and its downstream molecules in both
DLBCL cell lines (SUDHL-2 and SUDHL-4): p70S6K on
Thr389, a direct target of mTORC1; RPS6 on Ser235/
236, a substrate of p70S6K; and 4E-BP1 on Thr36/45
(Figure 1A and Additional file 1: Figure S1). Similar re-
sults were obtained when cells were treated with rapa-
mycin. In agreement with other reports, rapamycin did
not affect 4E-BP1 phosphorylation on Thr36/45 sites
[27]. To test the effect of both inhibitors on the mTORC2
pathway, we evaluated AKT phosphorylation. EtOH ex-
posure (like rapamycin) either did not change or, at higher
concentrations, increased AKT phosphorylation on both
Ser473 and Thr308, suggesting that a stronger dose of
EtOH might stimulate mTORC2 activity (Figure 1B).
In contrast, treatment with INK128 resulted in a
complete loss of AKT phosphorylation on Ser473 and
a strong decrease in phosphorylation of Thr308 in
both doses, confirming INK128’s inhibitory effect on
both mTORC1 and mTORC2 complexes. Consistent
results were obtained in experiments performed in several
B-lymphoblastoid cell lines derived from a healthy pa-
tient (Additional file 2: Figure S2), suggesting that both
lymphoma cells and normal lymphocytes respond in a
similar way to EtOH and INK128 with respect to mTOR
activity.
Subsequently, we examined the influence of EtOH and
INK128 on protein-protein interactions of the individual
mTORC1 and mTORC2 complex members. To this
aim, extracts from cells untreated or treated with EtOH,
INK128 or rapamycin were immunoprecipitated with
antibodies specific to mTOR and then immunoblotted
with raptor (component of mTORC1 complex) or rictor
(component of mTORC2 complex) antibodies (Figure 1C).
EtOH exposure decreased the relative abundance of the
raptor-mTOR complex while the mTOR-rictor interaction
increased, confirming EtOH’s inhibition of mTORC1 and
activation of mTORC2 pathways. Interestingly, despite the
strong inhibition of mTOR signaling by INK128 treat-
ment, there was either no effect or an increase in both
mTORC1 or mTORC2 complex formations with respect
to raptor and rictor association. In agreement with previ-
ous reports [28], rapamycin inhibited assembly of both
mTORC1 and mTORC2 in studied lymphoma cells.
There were no changes in the amount of total cellular
levels of rictor or raptor in these experiments. In sum-
mary, these data demonstrate that EtOH suppresses
mTORC1 activity and complex formation, while concomi-
tantly activating AKT (at both Thr308 and Ser473) and
mTORC2 assembly in a manner similar to the feedback
observed in rapamycin treatment. In contrast, INK128 ap-
pears to fully inhibit the activity of both mTORC1 and
Figure 1 Effect of EtOH and INK128 on mTORC1/2 activity in DLBCL cells. SUDHL-2 and SUDHL-4 cells were treated with either EtOH for
24 h, INK128 for 3 h at the concentrations as indicated, or 20 nM rapamycin (Rap.) for 3 h. (A) Cell lysates were analyzed by western blotting for
phosphorylation states and total levels of indicated proteins. Quantification of the signals is expressed as the percentage of the signal intensity
relative to the control group in each cell line. Graphs present the mean and standard deviation from two to five independent experiments.
*p≤ 0.05. (B) The levels of phosphorylated AKT at Ser473 and Thr308, and total AKT levels were assessed. (C) IP assays, using either IgG or
anti-mTOR antibodies, were performed to analyze association of mTOR with raptor and rictor. Immunoprecipitates and total cell lysates were
analyzed by immunoblotting (5 ug input). β-Actin served as a loading control. Data are representative of at least three independent experiments.
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complex.
EtOH and INK128 inhibit cap-dependent translation and
global protein synthesis
Given the role of mTOR in regulating cap-dependent
and global translation, we examined the potential for
EtOH and INK128 to influence protein synthesis inDLBCL. To test how decreased phosphorylation of
4E-BP1 upon EtOH or INK128 exposure (Figure 1A)
modulates 4E-BP1 and eIF4G association with eIF4E,
we incubated cell lysates with the 7-methyl-GTP (m7GTP)
cap bound to Sepharose beads. Consistent with EtOH’s in-
complete inhibition of 4E-BP1 phosphorylation on Thr36/
45 (Figure 1A and Additional file 1: Figure S1), EtOH treat-
ment modestly increased association of 4E-BP1 with eIF4E
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eIF4E is mutually exclusive, the EtOH-triggered accumula-
tion in 4E-BP1-eIF4E complexes appropriately decreasedFigure 2 Effect of EtOH and INK128 on translation of DLBCL cells. (A)
treated with INK128 or 20 nM rapamycin (Rap.), m7GTP cap analog pull-do
abundance were analyzed by western blotting along with the total protein
blots. (B,C) Cells were either untreated (Ctrl) or treated with 20 mM of EtO
through 10–50% linear sucrose gradients (lanes 1 through 11) and the dist
monosomes 80S and polysomes of increasing molecular weight were mon
(B,C) and incubated for 20 min with 35S-labeled amino acids. Cell lysates w
Nascent protein synthesis was quantified and graphed as a percentage of
of at least three independent experiments. Quantification of the signals is e
control group in each cell line. Graphs present the mean and standard deveIF4G-eIF4E interactions in both lymphoma cell lines.
INK128 treatment led to almost undetectable association
of eIF4G with eIF4E, accompanied by strikingly moreAt 48 h after cells were treated with EtOH and 24 h after cells were
wn reactions were performed. 4E-BP1, eIF4G, and eIF4E protein
levels. 10 μg of protein were used for Input and whole cell lysate
H for 48 h or 40 nM of INK128 for 24 h. Cell lysates were fractionated
ribution of mRNA associated with ribosomal subunits 40S and 60S,
itored by 245 nm absorbance. (D,E) Cells were treated as described in
ere resolved by SDS-PAGE and visualized with a PhosphorImager.
signal intensity relative to controls. The data shown are representative
xpressed as the percentage of the signal intensity relative to the
iation from two to five independent assays. *p≤ 0.05.
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pared to the effect of EtOH, while rapamycin had an inter-
mediate effect. No changes were observed in total levels of
studied protein.
Since the majority of protein synthesis is cap-
dependent, we further assessed the effects of EtOH or
INK128 on global mRNA translation. Global changes in
protein synthesis were measured using two experimental
approaches. First, we investigated the consequence of
each treatment on overall mRNA translation by moni-
toring the distribution of polysome formation. Cytoplas-
mic extracts from the untreated, EtOH, and INK128
treated cell cultures were fractionated on sucrose gradi-
ents and the association of mRNAs with the transla-
tional apparatus was monitored by 254 nm absorbance.
Although both EtOH and INK128 treated DLBCL
cultures displayed a reduction in the content of poly-
somes when compared with controls, INK128’s effect
was more prominent (Figure 2B,C). Second, we assessed
the incorporation of 35S-labeled amino acids into newly
translated protein after a short incubation with L-[35S]
methionine and L-[35S]cysteine. In agreement with the
polysomal data, we observed a significant decrease in
the rate of global nascent protein synthesis in both
EtOH and INK128 treated cells relative to the untreated
controls (Figure 2D,E). Overall, these results provide evi-
dence that, whereas both treatments suppressed cap-
dependent translation and global protein synthesis,
EtOH’s inhibitory effects are less pronounced when
compared to INK128.
EtOH induces while INK128 impairs stress granules
formation
Stress granules (SG) are cytoplasmic foci that accumulate
translationally silenced messenger ribonucleo-protein
(mRNP) under conditions that inhibit cap-dependent
translation initiation [29]. Recent evidence indicates
that SG also play a role in inhibition of the mTOR
pathway [30-32]. Therefore we investigated the potential
for EtOH or INK128 to trigger translational repression
through SG formation. SUDHL-2 cells were treated with
either EtOH or INK128 and fixed with paraformaldehyde.
SG were visualized by immunofluorescence through the
co-localization of the classical SG markers G3BP1 and
TIAR [33,34]. Corresponding to the EtOH-repressed
translation (Figure 2), EtOH treatment efficiently induced
SG assembly in a dose dependent manner (Figure 3A).
INK128 treatment, however, despite its greater inhibitory
effect on mTOR signaling and translation as compared to
EtOH (Figure 2), did not cause appearance of SG foci in
the SUDHL-2 cells (Figure 3B; upper panel). This result
and other’s data demonstrating that pharmacological in-
activation of the mTORC1-eIF4E pathway may impair SG
formation [35] prompted us to wonder whether the dualmTORC1/mTORC2 inhibition by INK128 (Figure 1)
resulting in an almost complete eIF4E-eIF4GI complex
disruption (Figure 2A) can alter the process of SG forma-
tion. In this case, SUDHL-2 cells pretreated with INK128
were next treated with sodium arsenite. As illustrated in
Figure 3B (lower panel) the number and size of SG assem-
bled upon arsenite treatment declined with increasing
dose when cells were pretreated with INK128, suggesting
that catalytic inhibition of mTOR by INK128 impairs the
SG response. Interestingly, rapamycin treatment neither
induced nor disrupted SG formation. Overall, these results
demonstrate the previously unreported finding that EtOH
treatment, in contrast to both rapamycin and INK128,
elicits a moderate inhibition of mTOR signaling and
translation while inducing SG assembly, while complete
mTOR inactivation, and the translational decline caused
by INK128 exposure, result in a failure to form SG.
EtOH and INK128 exposure distinctly modulate specific
gene translation
In order to better understand the molecular mechanisms
wherein EtOH or INK128 trigger global translational re-
pression, we attempted to gain insight into the mRNAs
affected by EtOH and INK128 at the translation level.
To this end, RNA isolated from translationally active
polysomal fractions (pooled fractions 9–11) was subjec-
ted to microarray analysis. Venn diagram analysis of the
common and specific genes changed within lymphoma
cell treatments revealed that EtOH was responsible for
modulating, at the translational level, 219 mRNAs
(120 mRNAs increased and 99 decreased) as compared
with control cells, in both SUDHL-2 and SUDHL-4 cells
(Figure 4A). In comparison, INK128 altered the abun-
dance of 409 transcripts (201 increased, 208 decreased) in
translationally active polysomal fractions as compared to
controls. Only 45 genes were found to be overlapping
between both treatments indicating that there is a differ-
ential mechanism by which both inhibitors act on mTOR
signaling.
Importantly, among the top genes significantly chan-
ged consistently in both lymphoma cell lines, we found
numerous genes involved in cellular functions, such as
AKT/mTOR signaling and protein synthesis (eg. FKBP4,
FKBP11, YWHAZ, MARS), cell cycle (eg. CDC25A,
CDC42), proliferation and apoptosis (eg. TCL1A, TCL1B,
LYN, CD27) (Figure 4B and Additional file 3: Table S1).
Therefore, six candidate genes representing each of the
pathways above were selected for further validation
(Figure 4C). EtOH and INK128 did not alter the total
mRNA levels for most of the validated transcripts, with
the exception of a ~2 fold decrease observed in FKBP11
mRNA upon EtOH treatment, and a ~3 fold increase in
TCL1A mRNA induced by INK128 treatment (Figure 4D).
These results indicate possible additional involvement of
Figure 3 EtOH induces while INK128 impairs stress granules formation. (A) SUDHL-2 cells were either left untreated or treated with
indicated doses of EtOH, and SG were detected using anti-G3BP1 (red) and anti-TIAR (green) antibodies. DAPI (blue) was used for nuclear staining.
(B) SUDHL-2 cells were treated with indicated concentrations of INK128 (Control) or preincubated with INK128 for 1 h and then treated with
250 μM arsenite for an additional 1 h (Arsenite). Cells were then analyzed by immunofluorescence as described in (A). Representative fields from
three independent experiments are shown. Typical SG are illustrated in enlarged pictures. Pictures were taken using a Nikon TE2000S.
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genes. In agreement with the microarray data, EtOH did
not modulate or only slightly changed the translational
profile of FKBP11, MARS, CDC25A, TCL1A and LYN
mRNAs, while INK128 treatment decreased levels of
FKBP11, MARS, CDC25A transcripts in the actively
translating fractions of the gradient (fractions 9–11) and
elevated levels of TCL1A and LYN mRNAs in these frac-
tions, with a subsequent mRNA shift in non-translating
(fractions 1–6) and low-translating (fractions 6–8) frac-
tions of the density gradient (Figure 5A). Reverse, we
found decreased translation of YWHAZ transcript in
EtOH treated groups with no changes upon INK128 treat-
ment as predicted by microarray analysis. No changes
were observed in housekeeping GAPDH mRNA used as
a loading control. In accordance with the differencesobtained in translational profiles, western blot analysis
showed concurrently altered protein levels of the six
candidate genes (Figure 5B).
To elucidate the potential for functional consequences
of EtOH and INK128 treatment, the significantly chan-
ged genes were subjected to Ingenuity Pathways Analysis
(IPA) and Gene Ontology (GO) analysis. In IPA analysis,
genes altered in both treatments were distributed into
networks defined by known molecular interactions. For
both treatments, the top networks with the highest
number of altered genes were molecular functions linked
to cell death and survival, cellular development, cellular
growth and proliferation, hematological system develop-
ment and function and tissue morphology (Additional
file 4: Table S2). GO analysis identifies biologically func-
tional categories that consist of genes altered upon
Figure 4 EtOH and INK128 influence on gene translation in DLBCL cells. Microarray analysis of translationally active (pooled fractions 9–11)
polysomal mRNAs following treatment either with EtOH (20 mM) for 48 h or INK128 (40 nM) for 24 h was performed in three independent
replicates. (A) Venn diagram comparison of EtOH and INK128 triggered translatome alteration in both SUDHL-2 and SUDHL-4 cell lines; transcripts
with significantly (criteria in Material and Methods) increased (red) or decreased (green) translation following treatments when compared to
untreated cells. (B) The heat map represents top transcripts with the most altered translation induced by EtOH and INK128. S2, SUDHL-2 cells; S4,
SUDHL-4 cells. (C) Examples of genes showing differences in mRNA translation followed by either EtOH or INK128 exposure. (D) Total mRNAs
levels of validated genes described in (C), measured by RT-qPCR in cells treated with EtOH or INK128 compared to untreated cells. Graphs
represent the mean and standard error of the mean from three repeats of three independent experiments.
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lation and translation-related GO terms encompassed the
greatest subset of genes significantly altered with INK128
treatment in both SUDHL-2 and SUDHL-4 lymphoma
cells (Additional file 5: Figure S3). These results suggest
that although both EtOH and INK128 affect subsets of
functionally related mRNAs, which are involved in cell
growth and survival, the effect of EtOH treatment on thetranslation of many of these mRNAs was less profound
than INK128.
Altogether, translatome analysis indicated that the ma-
jority of those transcripts which were impacted by either
treatment pertain to cell growth and survival. In addition,
microarray data demonstrated that INK128, affects the
synthesis of many proteins involved in the mTOR path-
way, translational control and cell proliferation more
Figure 5 Validation of microarray data. (A) SUDHL-2 cells were treated as described in Figure 4. Cell lysates were fractionated through sucrose
gradients and EtOH- or INK128-induced changes in translational profile of selected for validation genes (and housekeeping GAPDH mRNA) were
monitored by RT-qPCR analysis of RNA from each of 11 fractions. (B) Protein levels of validated genes were analyzed by western blotting. β-Actin
was used as a loading control. Rap., 20 nM rapamycin. Data are representative of three independent experiments.
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impact of these agents on overall protein synthesis rates.
EtOH and INK128 influence on cell cycle, proliferation and
apoptosis
Finally, we examined the influence of EtOH and INK128
on cell phenotype. In order to determine how the differ-
ences between EtOH and INK128 treatment, along with
the observed changes in mTOR signaling and gene
expression, impact DLBCL, we examined cell cycle,
proliferation and apoptosis. In both cell lines EtOH expos-
ure resulted in only a slight increase in cell cycle arrest,with higher doses (40 and 100 mM) showing a greater
percentage of cells in G0/G1 phase (Figure 6A and
Additional file 6: Figure S4). INK128 and rapamycin, how-
ever, induced stronger cell cycle arrest when compared to
EtOH. A dose dependent decrease in cell number was
observed with EtOH and INK128 treatment, compared to
the untreated cell populations (Figure 6B). Apoptosis was
measured by PI/Annexin V staining and confirmed by
western blot detection of Caspase-3 and PARP-1 cleavage.
Using flow cytometry, no significant evidence of apoptosis
was measured for cells treated with EtOH, 40 nM INK128
or rapamycin (Figure 6C and Additional file 7: Figure S5),
Figure 6 Influence of EtOH and INK128 on cell cycle, proliferation and apoptosis of DLBCL cells. Cells were treated with indicated doses
of EtOH or INK128 as described in Material and Methods. (A) At 48 h after treatment, cells were stained with PI and cell cycle distribution was
monitored by flow cytometry. (B) At 72 h after indicated treatments, cell numbers were counted with a hemocytometer, (C) cells were stained
with Annexin V and PI, and percent of apoptotic cells was measured by flow cytometry or (D) cleavage of PARP-1 and Caspase-3 was analyzed
by western blotting. β-Actin served as a loading control. The data are representative of at least three independent repeats. In the graphs (A), (B)
and (C), the means and SD are shown. *p≤ 0.05. Rap., 20 nM rapamycin.
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(Figure 6D). However, treatment with 200 nM of INK128,
resulted in a 20-40% increase in apoptotic cells, as
evidenced by PARP-1 cleavage in both SUDHL-2 and
SUDHL-4 cell lines. These observations indicate that
EtOH is cytostatic, even at its highest dose (100 mM),
while increasing the concentration of INK128 from 40 to
200 nM results in cytotoxicity within the two DLBCL cell
lines tested.
EtOH induces autophagy but not apoptosis in DLBCL
Since mTORC1 regulates autophagy, and inhibition of
mTOR has been shown to induce autophagic activity[36,37], we explored the potential of EtOH and INK128
to induce autophagy through the assessment of the
autophagy marker microtubule-associated protein 1 light
chain 3 (MAP1LC3 or LC3) in DLBCL. In the process of
autophagy induction, LC3 is lipidated from the soluble
form (LC3-I) to the autophagosome-associated form
(LC3-II), which ultimately results in the formation of
LC3-positive puncta (autophagosomes) within the cells
[38]. Upon SUDHL-2 cell exposure to EtOH and
INK128, as well as rapamycin, we observed increased
autophagosome formation as visualized by LC3-positive
puncta in immunofluorescent analysis (Figure 7A). Cells
were also assessed by western blot to detect LC3-I
Figure 7 EtOH and INK128 induce autophagy. (A) SUDHL-2 cells were treated with 10 μM Chloroquine and with indicated doses of EtOH,
INK128 or rapamycin for 6 h. LC3A positive autophagic puncta (arrows show examples) were visualized under fluorescence microscopy. Pictures
were taken using a Nikon TE2000S (B) Cells were treated as in (A) with or without Chloroquine. Cell lysates were then analyzed for abundance of
LC3 forms by western blotting. β-Actin was used as a loading control. The data are representative of three independent experiments.
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autophagosome form (LC3-II) by western blotting in all
doses and treatments (Figure 7B). In summary, the ob-
served induction of autophagy by both EtOH and
INK128 combined with the dose dependent induction
of apoptosis by INK128 but not by EtOH treatment
(Figure 6D) further corroborates a limited suppression
of mTOR by EtOH, as opposed to the potent mTOR in-
activation by INK128 with respect to cellular phenotype
and subsequent cell fate (Figure 8).
Discussion
mTOR is a central node in the regulation of critical
cellular processes including protein synthesis, cell
growth and metabolism, which are often aberrantly stim-
ulated in many pathologies including cancer. To date,
many pharmacological inhibitors have been discovered
which inhibit mTOR signaling, from the classical allo-
steric inhibitor, rapamycin, to more recent active site
inhibitors such as PP242, Torin1, AZD8055 and INK128,
[7,26,27,39]. Nevertheless, due to the many molecular
levels regulating mTOR signal transduction, compoun-
ded by cell type specificity, the exact mechanisms ofregulation and the impact of current therapeutics re-
main underdeveloped [40]. While EtOH has been
shown to inhibit the mTORC1 signaling pathway, these
studies have mostly been performed on non-human tis-
sue [12,13,22-25], there have been few studies on hu-
man malignancy [14]. In contrast to most cancer types,
a growing number of population studies have shown an
inverse correlation between EtOH consumption and
incidence of hematological malignancy [17-21]. How-
ever, the mechanisms behind EtOH-based regulation of
mTOR components, mTORC1 and mTORC2, and their
functional consequences in hematological malignancies
are poorly understood.
In this study, we chose the catalytic mTOR inhibitor
INK128 to compare with EtOH for the purpose of eluci-
dating convergent and divergent pathways between the
two treatments, in the context of DLBCL. INK128 is a
second-generation ATP-competitive mTOR inhibitor
that binds the mTOR catalytic domain and selectively
inhibits both mTORC1 and mTORC2, and is currently
in clinical trials [26,41,42]. We have demonstrated that
treatment of DLBCL with EtOH suppressed mTORC1
activity in a dose dependent manner with concomitant
Figure 8 Schematic of EtOH and INK128 impact on the mTOR pathway and cellular response. Broken lines indicate no change or moderate
increase.
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and Ser473, whereas the dual mTORC1/2 inhibitor
INK128 completely abrogated AKT phosphorylation at
these sites. While Akt phosphorylation was increased
with EtOH treatment there was no concomitant increase
in mTOR S2448 phosphorylation. Given that intact
mTORC1 complex is required for specific S2448 mTOR
site phosphorylation [43] it is conceivable that EtOH-
induced disruption of the raptor-mTOR complex
(Figure 1C) prevented mTOR from Akt mediated
phosphorylation. Our finding that EtOH decreased
raptor-mTOR association while increasing rictor-mTOR
complex formation provides strong evidence for EtOH
not only having a suppressive effect on mTORC1 but also
an activating role in the mTORC2 pathway. Breuleux
et al. (2009) demonstrated that selective mTORC1 sup-
pression by RAD001, or knock down of raptor, elicits
increased AKT S473 phosphorylation, requires rictor and
can be modulated by mTORC2 complex [44]. I addition,
it was found that the rictor-mTOR complex directly phos-
phorylated AKT/PKB at Ser473, which facilitated Thr308
phosphorylation by PDK1 [5]. It is also possible that,
EtOH may modulate the Akt-mTOR interaction, Akt
catalytic activity or subcellular location. Activation ofp70S6K has been shown to modulate the phosphorylation
mTOR S2448 [45], so it may be that through the inhib-
ition of p70S6K (via mTORC1 disruption) that AKT is no
longer able to physically interact with and phosphorylate
the S2448 site. Although previous research has de-
monstrated EtOH’s effect on mTOR to be both TSC1/2
and AMPK independent [14], EtOH may affect other
unknown upstream kinases. Nearly full inhibition of
mTORC1 and mTORC2 by INK128, however, did not
cause changes in or slightly increased mTORC1/2 com-
plex formation. This is likely due to a much stronger abla-
tion of the negative feedback mechanisms that drive
raptor and rictor dissociation, keeping complex activity
balanced [46].
mTOR is known to modulate cap-dependent transla-
tion through the phosphorylation of the translation in-
hibitor 4E-BP1 and to subsequently prevent 4E-BP1
binding to eIF4E [6,47,48]. eIF4E is an essential compo-
nent in initiating cap-dependent translation via its bind-
ing to 5’ 7-methyl-GTP cap structure on mRNAs, which
stimulates formation of the cap-binding eIF4F complex
through its interaction with the scaffolding protein
eIF4G [49-51]. Since 4E-BP1 directly competes with
eIF4G for the same eIF4E-binding site, mTORC1-
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binding to eIF4E, recruitment of the 40S ribosomal sub-
unit to the 5′ cap and enhanced cap-dependent transla-
tion initiation [51-53]. Fournier et al. (2013) reported
that mTORC1, through the phosphorylation of 4E-BP1
and consequent regulation of eIF4E-eIF4G association,
facilitates SG formation [35]. We discovered that EtOH
resulted in inhibition of mTORC1 phosphorylating
4E-BP1, consequently causing a moderate reduction
in eIF4E-eIF4G complex assembly and promoting as-
sembly of SG. We further demonstrated that INK128-
induced mTOR inhibition almost completely abolished
the mTORC1-eIF4E pathway, leading to impaired SG
formation. This result is consistent with the recent data
showing that pharmacological inactivation of the mTOR
pathway by PP242 resulted in failure of SG assembly
[35]. The authors demonstrated that PP242-induced
hypo-phosphorylation of 4E-BP1 and abrogation of
eIF4E-eIF4G interaction by 4E-BP1 prevents eIF4E-
mediated SG formation. We thus postulate that, similar
to PP242, a possible mechanism by which INK128 im-
pairs SG formation is the complete disruption of eIF4E-
eIF4G complex by 4E-BP1, following treatment. Given
that eIF4E-eIF4G complexes might be essential for
assembly of SG under mild stress conditions [35], we
speculate that the moderate decrease in mTOR signal-
ing caused by EtOH and consequent eIF4E-eIF4G par-
tial association allow for and promote SG formation.
However, future experiments are needed to establish the
role mTOR signaling in SG formation.
Using microarray analysis of actively translated polyso-
mal mRNA, we found that EtOH affected the translation
of fewer mRNAs than INK128. Intriguingly, almost 80%
of the genes did not overlap between the two treatments,
indicating that EtOH and INK128 exposure distinctly
modulate the DLBCL translatome while confirming a
previous study which detailed distinct translational
profiles with different mTOR inhibitors [48]. Despite
finding that most of the genes were unique to each treat-
ment, many of those genes differentially controlled by
EtOH and INK128 are involved in similar pathways such
as AKT/mTOR signaling, protein synthesis, cell cycle,
proliferation and apoptosis. It has been previously
reported that some of the mRNAs involved in protein
synthesis and translationally controlled by mTOR may
contain 5’ terminal oligopyrimidine (5’TOP) or TOP-like
pyrimidine-rich translational element (PRTE) motifs
within their 5’ untranslated regions (5’ UTRs) [26,54-56].
We found that 21.4% of the INK128 regulated genes
possess a PRTE-like motif, however instead of thymidine
enrichment in the 6th position, thymidine appears in the
5th (Additional file 8: Figure S6). In the group of genes
whose expression was altered by EtOH treatment, no
statistically significant motifs were found. However,future studies are needed to determine the regulatory
mechanism for these sequences and their involvement
in the mTOR drug response.
The fact that EtOH treatment less markedly affected
gene expression is consistent with EtOH incompletely
interfering with the activity of mTORC1 when compared
to the efficient inhibition of mTORC1-dependent eIF4E
activation by INK128. Our findings further establish that
although the end result of mTOR inhibition is a global
decrease in protein synthesis, differential inhibition of
mTOR signal transduction may distinctly modulate trans-
lation of specific subsets of mRNAs that control the key
cellular processes responsible for cell fate.
Despite its modest effect on translation, treatment
with EtOH resulted in a similar cellular phenotype to
INK128, albeit weaker, by inhibiting cell cycle progres-
sion and proliferation while promoting the induction of
autophagy. While active mTORC1 promotes cell growth,
it also negatively regulates autophagy through the
phosphorylation-driven repression of the ULK1/Atg13/
FIP200 kinase complex. Autophagy involves the cellular
degradation of unnecessary or dysfunctional cellular com-
ponents via lysosomes. This degradative pathway pro-
motes cell survival during starvation or other stressors by
maintaining cellular energy levels. With respect to cancer,
autophagy is often associated with a pro-survival pheno-
type, whereas in other cases it can promote cell death
[57]. It is therefore interesting that INK128, although re-
sponsible for the induction of autophagy, also induced cell
apoptosis, suggesting that while EtOH decreases DLBCL
cell viability, full inhibition of mTOR cannot be salvaged
by autophagy. Finally, it is important to note that in con-
trast to the specific activity of INK128, EtOH can exert
many pleiotropic effects in addition to the suppression of
mTOR signaling and protein synthesis. Ethanol exposure
has been shown to produce reactive oxygen species (ROS)
and elicit an oxidative stress response [22]. Ethanol has
also been shown to induce ER stress-mediated neuronal
cell death thus limiting the interpretation of our data [23].
It remains to be determined if other pleiotropic effects of
EtOH participate in, or can account for, its overall influ-
ence on hematological malignancies.
Conclusions
In summary, we provide evidence that EtOH partially in-
hibits mTOR activity compared to INK128’s complete
suppression of mTOR, resulting in differential regulation
of downstream mTOR targets and consequent differ-
ences in cellular responses and cell fate (Figure 8). Al-
though INK128 can fully inhibit the activity of mTOR,
we have shown through a comprehensive investigation
of signal transduction, translatome analysis, and pheno-
typic observation that when comparing EtOH treatment
to an equipotent dose of INK128, significant differences
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hematological malignancy in alcohol consumers. These
findings additionally support a model for mTOR func-
tioning as a ‘master’ upstream regulator of a functionally
related subset of mRNAs and further reveals the com-
plexity of its control.
Materials and methods
Cell culture and treatments
The collection of tissues was determined by our University
of Maryland Medical School IRB to be Not Human Sub-
jects Research, as no identifying information was collected
from subjects, therefore no written informed consent was
required or collected. SUDHL-2 and SUDHL-4 diffuse
large B-cell lymphoma (DLBCL) cell lines (ATCC) were
cultured in RPMI Medium 1640 (Gibco BRL) supple-
mented with 10% fetal bovine serum (FBS) at 37°C in 5%
CO2, as previously described [58]. Cells were treated with
EtOH at concentrations of 20, 40 or 100 mM for 24 h,
unless differently specified, and cultured in sealed flasks to
maintain EtOH concentrations in the culture medium, as
previously described [13,22,25]. Cells were treated with
INK128 (Selleckchem) dissolved in dimethyl sulfoxide
(DMSO). Rapamycin (Sigma) was used at a concentration
of 20 nM. Vehicle controls were treated with 0.01%
DMSO.
Primary human tonsillar B-cell isolation and lymphoblastoid
cell line generation
Primary human tonsillar B-cells were provided by the
University of Maryland Greenebaum Cancer Center
Pathology Biorepository and Research Core from routine
tonsillectomies in accordance with the guidelines of the
University of Maryland Medical School Institutional Re-
view Board and conform to the Declaration of Helsinki.
Tonsils were minced on ice and lymphocyte populations
were separated by Ficoll, washed in Hank’s Balanced Salt
Solution (HBSS) and stained with CD19-APC (BD
Bioscience), CD38-FITC (BD Bioscience) and IgM-PE
(eBioscience) in HBSS containing 5% FBS. Cells were
then sorted through a 70 μM nozzle on a FACSAria
II (BD Bioscience) cell sorter to a purity of greater
than 99%. Both CD19+/CD38+/IgM- (germinal center)
and CD19+/CD38-/IgM+ (naive) B-cells were then cul-
tured in RPMI containing 10% FBS, 1% Pen/Strep and 1%
amphotericin B while in the presence of Epstein-Barr virus
(EBV) (ATCC VR-1492) for 6 weeks until outgrowth was
observed.
Western blotting and co-immunoprecipitation assay
For western blot analysis, protein lysates (10–50 μg)
were size-separated by SDS-PAGE (Invitrogen), trans-
ferred onto PVDF membranes and probed with the
indicated antibodies. Blots were probed with polyclonalrabbit antibodies recognizing p-mTOR (Ser 2448), mTOR,
p-p70 S6 kinase (Thr 389), p70 S6 kinase, p-RPS6 (Ser
235/236), RPS6, p-4E-BP1 (Thr 36/45), 4E-BP1, p-AKT
(Ser 473), p-AKT (Thr 308), Lyn, eIF4G, Caspase-3 and
LC3A/B (Cell Signaling Technology), eIF4E, PARP-1,
YWHAZ (Santa Cruz Biotechnology), Raptor, Rictor,
MARS (Bethyl Laboratories), AKT (Upstate), polyclonal
goat anti-FKBP11 antibody from Santa Cruz Biotechnol-
ogy, or monoclonal mouse antibodies recognizing β-Actin
(Abcam), CDC25A and TLC1A (Santa Cruz Biotech-
nology). After incubation with appropriate secondary
antibodies, signals were detected by enhanced che-
miluminescence (Pierce). For co-immunoprecipitation
assays, IgG or mTOR antibodies (Cell Signaling Tech-
nology) were added to 0.2 mg protein lysates and
incubated overnight at 4°C. Following incubation (1 h,
4°C) with Protein A-Sepharose beads (Invitrogen)
complexes were washed three times with NT2 buffer
(50 mM Tris pH 7.4, 150 mM NaCl, 1 mM MgCl2,
0.05% NP-40) and analyzed by western blotting.Polyribosome fractionation
Cells were lysed in cytoplasmic lysis buffer (5 mM Tris,
2.5 mM MgCl2, 1.5 mM KCl, 1% Triton X-100, 0.5%
Sodium Deoxycholate and 2 mM DTT), loaded on 10 -
50% linear sucrose gradients and fractionated as previ-
ously described [58,59]. The RNA in each fraction was
monitored by optical density measurement (A254) and
eleven fractions were collected with a fraction collector
(Brandel). The RNA from each fraction was isolated by
Trizol (Invitrogen) and used for RT-qPCR analysis. RNA
from high molecular weight polysomal fractions, with
actively translated mRNAs (fractions 9–11), were pooled
and used for microarray analysis.Analysis of newly translated protein
Analysis of de novo translation was performed as repor-
ted previously [58]. Briefly, after treatments, cells were
incubated with L-[35S]methionine and L-[35S]cysteine
(Easy Tag EXPRESS; NEN/Perkin-Elmer) for 20 min and
radiolabel incorporation was monitored by resolving cell
lysates on SDS-PAGE followed by transfer onto PVDF
membranes and visualization with a PhosphorImager
(GE Healthcare).m7GTP pull-down and luciferase assay
7-methyl-GTP cap analog pull-down was carried out as
previously described [58]. Shortly, 500 ug of total cell
lysates were incubated with the 7-methyl-GTP cap ana-
log bound to Sepharose beads (Jena Bioscience), washed,
and the cap-bound protein complex was eluted and ana-
lyzed by western blotting.
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Cells were fixed in 1% paraformaldehyde and perme-
abilized in PBS with 0.5% Triton X-100. After washing
with 0.1% PBST, cells were incubated in IF blocking buf-
fer (3% BSA, 0.1% Tween-20 in PBS) for 1 h at RT. Cells
were then incubated overnight at 4°C with mouse anti-
G3BP1, goat anti-TIAR (Santa Cruz Biotechnology), or
sheep anti-LC3A (Abcam) antibodies in blocking buffer
(1:200) and washed with PBS + 0.1% Tween-20. They
were further incubated for 1 h at RT with the appropri-
ate secondary goat anti-mouse Alexa Fluor 568, donkey
anti-sheep Alexa Fluor 488 and donkey anti-goat Alexa
Fluor 488 secondary antibodies (Molecular Probes; 1:200
dilution) and washed with PBS + 0.1% Tween-20. The
stained cells were seeded on slides and mounted using
ProLong Gold mounting medium with DAPI (Invitrogen).
Photos were taken using a fluorescence microscope
(Nikon TE2000S).Analysis of cell cycle, apoptosis and autophagy
Cells were fixed with 70% EtOH, washed with PBS,
stained using PI/RNase staining buffer (BD Biosciences)
and analyzed for cell cycle with a flow cytometer. Apop-
tosis was analyzed by flow cytometry with the PI/
Annexin V staining kit (BD Biosciences). Autophagy was
analyzed by treatment with 10 μM chloroquine diphos-
phate (Sigma) and with either EtOH, INK128 or rapamy-
cin for 6 h. Appearance of LC3A positive autophagic
puncta was assessed by immunofluorescence microscopy
and, indicative of autophagic activity, conversion of LC3-
I to LC3-II was monitored by western blotting.Microarray data analysis
Microarray and data analysis was performed as previ-
ously described [58]. Briefly, RNA isolated from sucrose
fractions was labeled with Illumina TotalPrep RNA
Amplification Kit (Ambion; Austin, TX) and analyzed
using human HT-12 v1.0 gene expression BeadChips
containing 48,000 RefSeq transcripts (Illumina, San
Diego, CA). Microarray data were filtered by the detec-
tion p-value ≤ 0.02, normalized by Z-score transform-
ation, tested for significant differences in signal intensity
and analyzed for sample quality. Genes were considered
significantly changed after calculating Z-ratio, indicating
fold difference (Z > 1.5 or < −1.5), false discovery rate
(fdr ≤ 0.3) and p <0.05. Differentially expressed genes
were analyzed by Ingenuity Pathways Analysis (IPA) to
identify the top functional networks and Gene Ontology
(GO) analysis to identify key biological categories that
were significantly changed in EtOH- or INK28-treated
versus untreated control cells. See GEO database www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62790 for
complete microarray data.RT-qPCR analysis
Total and polysomal RNA were reverse transcribed with
the iScript cDNA synthesis kit (Quanta Biosciences),
and qPCR analysis was carried out using iQ SYBR Green
Supermix (Quanta Biosciences) on a BioRad CFXCon-
nect instrument. Oligonucleotides used for detection of
specific mRNAs in each fraction from sucrose gradients
are as follows: CTGGCTAAAGCTGGTGAAGG and
TGGGTCTATTGGCCTTTCTG for FKBP11 mRNA,
CCGCTGGTTTAACATTTCGT and TCAGCAACTGC
TGGAAAATG for MARS mRNA, CATGGACTCCAGG
AGGGTAA and TCACAGGTGACTGGGGTGTA for
CDC25A mRNA, TATGACCCCCACCCAGATAG and
ACTAAGCGCCAGAAACTGGA for TCL1A mRNA,
GGAGGAGCCCATTTACATCA and ATGTATGCCAT
TCCCTCTGC for LYN mRNA, AGACGGAAGGTGCT
GAGAAA and GAAGCATTGGGGATCAAGAA for
YWHAZ mRNA and, CGGAGTCAACGGATTTGGTC
GTAT and AGCCTTCTCCATGGTGGTGAAGAC for
GAPDH mRNA.
Additional files
Additional file 1: Figure S1. DLBCL cells were treated with EtOH for
24 h or with INK128 for 3 h at the indicated concentrations. Cell lysates
were analyzed by western blotting. β-Actin served as a loading control.
The data are representative of three independent experiments.
Additional file 2: Figure S2. EtOH and INK128 influence on mTORC1/2
activity in B-lymphoblastoid cell lines. GCB or naïve B-cells were treated
with EtOH for 24 h, with INK128 for 3 h at the concentrations as
indicated, or 20 nM rapamycin (Rap.) for 3 h and the phosphorylation
states and total levels of indicated proteins were detected by western
blotting.
Additional file 3: Table S1. Genes with the most altered translation
induced by EtOH and INK128 in DLBCL cells.
Additional file 4: Table S2. The top five functional networks identified
by Ingenuity Pathways Analysis (IPA) from the genes translationally
regulated by EtOH or INK128.
Additional file 5: Figure S3. Functional categories of polysome-associated
mRNAs in EtOH (20 mM) and INK128 (40 nM) treated DLBCL cells. Heat map
represents the top annotations with greatest representation of altered genes.
Additional file 6: Figure S4. Representative picture of flow cytometry
cell cycle analysis performed 48 h after SUDHL-2 cells treated with
indicated doses of EtOH, INK128 or 20 nM rapamycin (Rap.).
Additional file 7: Figure S5. Representative picture of flow cytometry
analysis of Annexin V/PI staining in SUDHL-2 cells 72 h after treatment
with indicated doses of EtOH, INK128 or rapamycin.
Additional file 8: Figure S6. Pyrimidine Rich Translational Element
(PRTE) motif found within the 5’ UTRs of 21.4% of INK128 responsive
translationally regulated mRNAs by MEME (Multiple EM for Motif
Elucidation).
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